Equity Profile

BNTX

BioNTech SE

Health CareBiotechnology$23.1B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

BioNTech SE is a biotechnology company focused on developing and commercializing innovative therapies for cancer and infectious diseases. With a market cap of $23 billion, it plays a significant role in the healthcare sector, especially following its prominence in COVID-19 vaccine development.

Key Metrics to Watch

EPS

Earnings per share (EPS) is crucial as it reflects the company's profitability and is a key indicator for investors.

$-2.08

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$156M

Wall Street expectations, options signals, track record, and call prep available with Pro.

BNTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+9.61%

Avg Stock Reaction

-4.09%

Last Quarter Recap

In Q1 2026, BioNTech reported an EPS of $-2.28, which was better than the expected $-2.52, resulting in a 9.45% surprise. However, the stock dropped 3.88% the following day, indicating market concerns.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are anticipating a challenging quarter for BioNTech, with expected losses continuing as the company navigates post-COVID market dynamics. The consensus EPS of $-2.08 suggests ongoing concerns about profitability.

Bull Case

If BioNTech can exceed revenue expectations and show signs of recovery in its core business, it could signal a turnaround, boosting investor confidence.

Bear Case

Continued losses and lower-than-expected revenue could further erode investor trust, leading to a more significant decline in stock price.

Key Metrics to Watch

EPS

$-2.08

Earnings per share (EPS) is crucial as it reflects the company's profitability and is a key indicator for investors.

Revenue

$156M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will BioNTech's revenue exceed the consensus estimate of $156 million?

Revenue performance is critical for assessing the company's market position and growth potential, especially in a post-pandemic environment.

How does management plan to address ongoing losses reflected in the expected EPS of $-2.08?

Understanding management's strategy for profitability will be key for investors looking for signs of a turnaround.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for revenue recovery as BioNTech expands its product pipeline beyond COVID-19 vaccines.

Supporting Evidence

The stock has shown a tendency to react positively to unexpected revenue growth, even amid losses.

Historical data indicates that the company has a 63% EPS beat rate, suggesting potential for positive surprises.

Key Risk

If revenue comes in below $99 million, it would significantly challenge the current market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether BioNTech can stabilize its financial performance after a period of significant volatility.

Bull Confirmed If

A revenue figure above $215 million would indicate strong market demand and validate a bullish outlook.

Bear Confirmed If

If revenue falls below $99 million, it would confirm concerns about the company's market viability.

Pre-Earnings Positioning

Options Market

Implied Move

±10.69%

Historical Avg

±4.7%

Pricing rich

The options market is pricing in a significant move around the earnings report, indicating uncertainty about the results.

Options are pricing ±10.7% while BNTX has averaged ±4.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

37.4%

Calls (22K)P/C Ratio: 0.41Puts (26K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioNTech beats expectations, history suggests the stock could rise by about 2.09%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss on earnings could lead to a decline of around 7.43%, reflecting ongoing investor concerns about the company's future.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on any new product developments beyond COVID-19 vaccines.
2Management's commentary on cost management strategies.
3Insights into market demand for BioNTech's current and future products.
4Any partnerships or collaborations that could enhance revenue streams.
5Guidance on expected timelines for upcoming clinical trials.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share (EPS) is crucial as it reflects the company's profitability and is a key indicator for investors.

$-2.08

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$156M

Wall Street expectations, options signals, track record, and call prep available with Pro.

BNTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+9.61%

Avg Stock Reaction

-4.09%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If BioNTech can exceed revenue expectations and show signs of recovery in its core business, it could signal a turnaround, boosting investor confidence.

Bear Case

Continued losses and lower-than-expected revenue could further erode investor trust, leading to a more significant decline in stock price.

Key Metrics to Watch

EPS

$-2.08

Earnings per share (EPS) is crucial as it reflects the company's profitability and is a key indicator for investors.

Revenue

$156M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will BioNTech's revenue exceed the consensus estimate of $156 million?

Revenue performance is critical for assessing the company's market position and growth potential, especially in a post-pandemic environment.

How does management plan to address ongoing losses reflected in the expected EPS of $-2.08?

Understanding management's strategy for profitability will be key for investors looking for signs of a turnaround.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for revenue recovery as BioNTech expands its product pipeline beyond COVID-19 vaccines.

Supporting Evidence

The stock has shown a tendency to react positively to unexpected revenue growth, even amid losses.

Historical data indicates that the company has a 63% EPS beat rate, suggesting potential for positive surprises.

Key Risk

If revenue comes in below $99 million, it would significantly challenge the current market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether BioNTech can stabilize its financial performance after a period of significant volatility.

Bull Confirmed If

A revenue figure above $215 million would indicate strong market demand and validate a bullish outlook.

Bear Confirmed If

If revenue falls below $99 million, it would confirm concerns about the company's market viability.

Pre-Earnings Positioning

Options Market

Implied Move

±10.69%

Historical Avg

±4.7%

Pricing rich

The options market is pricing in a significant move around the earnings report, indicating uncertainty about the results.

Options are pricing ±10.7% while BNTX has averaged ±4.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

37.4%

Calls (22K)P/C Ratio: 0.41Puts (26K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioNTech beats expectations, history suggests the stock could rise by about 2.09%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss on earnings could lead to a decline of around 7.43%, reflecting ongoing investor concerns about the company's future.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on any new product developments beyond COVID-19 vaccines.
2Management's commentary on cost management strategies.
3Insights into market demand for BioNTech's current and future products.
4Any partnerships or collaborations that could enhance revenue streams.
5Guidance on expected timelines for upcoming clinical trials.